DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Use of Donepezil for Treatment of Cocaine Dependence

Information source: Department of Veterans Affairs
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cocaine Abuse and Dependence

Intervention: Donepezil, 5 mg daily (Drug); Oral Placebo (Other)

Phase: Phase 2

Status: Completed

Sponsored by: Department of Veterans Affairs

Official(s) and/or principal investigator(s):
Kenneth Grasing, MD, Principal Investigator, Affiliation: Department of Veterans Affairs


The purpose of this study is to determine the safety of intravenous cocaine in subjects receiving oral donepezil.

Clinical Details

Official title: Donepezil Effects on Cocaine Craving and Pharmacokinetics

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Cocaine Safety in Subjects Receiving Donepezil

Secondary outcome:

Cocaine Subjective Effects

Cocaine Pharmacokinetics

Detailed description: This is a randomized, double-blind, double-dummy, placebo controlled, inpatient, single-center, parallel group evaluation of the potential for oral donepezil to attenuate cocaine-induced craving. Non-treatment-seeking cocaine-experienced volunteers will receive baseline treatment with intravenous cocaine (30Mg). Forty-two subjects that tolerate baseline cocaine infusions will then receive two subsequent intravenous doses of cocaine during double-blind treatment with oral placebo or 5 mg daily of donepezil. Each dose of cocaine will be preceded or followed by administration of intravenous placebo (saline) in a random order.


Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.


Inclusion Criteria:

- Non-treatment seeking, experienced cocaine users, who have used cocaine by smoking or

intravenous injection within the four weeks prior to screening, and must supply a cocaine-positive urine obtained within four weeks of entry into the study. Exclusion Criteria:

- Shows signs of psychostimulant toxicity, or has a history of a medical adverse

reaction to cocaine or other psychostimulants, including loss of consciousness, chest pain, cardiac ischemia, or seizure.

- Has a current psychiatric disorder other than drug abuse or dependence or dementia.

- Meets the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for

dependence to opiates, benzodiazepines, alcohol, or other sedative-hypnotics.

- Has received opiate-substitution therapy (methadone or buprenorphine) within two

months prior to enrollment.

- Has current or past history of seizure disorder, including alcohol- or

psychostimulant- related seizures, or family history of seizure disorder.

- Has a diagnosis of adult asthma, or chronic obstructive pulmonary disease, including

a history of acute asthma within the past two years, and those with current or recent (with the past two years) treatment with an inhaled or oral beta-adrenergic agonist.

- Has had head trauma that resulted in neurological sequelae.

- Has an unstable medical condition, which, in the judgement of investigators, would

make participation hazardous.

Locations and Contacts

VA Medical Center, Kansas City, Missouri 64128, United States
Additional Information

Starting date: February 2007
Last updated: May 21, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017